The accelerating cash burn and shortened runway from missed debt milestones are the primary concerns, the company now has ~3 quarters of cash at current burn rates. The Phase 3 ALLOHA-2 trial won't read out until mid-2028, meaning significant dilution or partnership financing is likely needed. Monitor for equity offering or collaboration deal to extend runway.
Drug in focus
TCRX drug pipeline →TSC-101
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 3 (paused)
- Time to market
- Uncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.
- Next catalyst
- None dated
What to watchTSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.
Price Chart
Executive Summary
TScan Therapeutics reported Q2 2026 results with revenue of $1.1M (down 66% YoY from $3.1M) and a net loss of $30.4M ($-0.23 EPS), missing the $-0.20 consensus estimate. The company dosed the first patient in its Phase 3 ALLOHA-2 trial and shared positive initial Cohort C data, but cash burn accelerated with cash dropping to $100.2M (from $128.1M in Q1), and the cash runway was shortened to Q2 2027 due to missed debt milestones triggering loan amortization.
Key Financial Metrics
Key Facts
- Revenue fell 66% YoY to $1.1M from $3.1M, driven by timing of Amgen collaboration activities
- Net loss of $30.4M ($-0.23 EPS) vs consensus $-0.20, a 15% miss
- Cash and cash equivalents dropped to $100.2M from $128.1M at Q1 end and $152.4M at year-end 2025
- Cash runway shortened to Q2 2027 (from prior Q2 2027) due to missed non-covenant milestones triggering two-year term loan amortization starting Q4 2026
- First patient dosed in Phase 3 ALLOHA-2 trial; topline readout expected mid-2028
- Positive initial Cohort C data: 79% (11/14) achieved complete donor chimerism; ~90% manufacturing success rate
- Pro forma share count essentially flat at ~130M shares
Financial Impact
Revenue decline of $2.0M (66% YoY); net loss of $30.4M; cash burn of ~$27.9M in Q2; cash runway shortened to Q2 2027
Risk Factors
- Cash runway only into Q2 2027 with no revenue growth catalyst; likely need for dilutive financing
- Phase 3 ALLOHA-2 topline data not expected until mid-2028, binary event risk far out
- Revenue concentration on Amgen collaboration with declining contribution
- Missed debt milestones triggering loan amortization adds cash outflow pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-345732 |
| Document: tcrx-20260812.htm | 0001193125-26-345732 |
| Document: 0001193125-26-345732-index-headers.html | 0001193125-26-345732 |
| Document: 0001193125-26-345732-index.html | 0001193125-26-345732 |
| Document: 0001193125-26-345732.txt | 0001193125-26-345732 |
| 8-K Data (Synthetic) | 0001193125-26-345732 |
Track record
15 reports on TCRX
6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 Viewing No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers